Appointment of Nominated Adviser and Sole Broker

Destiny Pharma plc
(“Destiny Pharma” or “the Company”)

Appointment of Nominated Adviser and Sole Broker

Brighton, United Kingdom ‐ 22 January 2024 ‐ Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused
on the development and commercialisation of novel medicines to prevent and cure life threatening infections, is pleased to
announce the appointment of Shore Capital and Corporate Limited as its Nominated Adviser and Shore Capital
Stockbrokers Limited as its Sole Broker with immediate effect.

‐ END ‐

For further information, please contact:

Destiny Pharma plc
Chris Tovey, CEO
Shaun Claydon, CFO
+44 (0) 127 370 4440
pressoffice@destinypharma.com

Shore Capital (Nominated Adviser and Broker)
Daniel Bush / James Thomas / Lucy Bowden
+44 (0) 207 408 4090

FTI Consulting (Financial PR)
Ben Atwell / Simon Conway / Michael Trace / Victoria Foster Mitchell
+44 (0) 203 727 1000
destinypharma@fticonsulting.com

About Destiny Pharma
Destiny Pharma is an innovative, clinical‐stage biotechnology company focused on the development and
commercialisation of novel medicines that can prevent life‐threatening infections. The company’s drug development
pipeline includes а late stage asset – XF‐73 nasal gel, a
proprietary drug targeting the prevention of post‐surgical staphylococcal hospital infections including MRSA.
For further information on the company, please visit destinypharma.com